Spots Global Cancer Trial Database for Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
Official Title: A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors
Study ID: NCT01765790
Study Description
Brief Summary: The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Scottsdale Healthcare, Scottsdale, Arizona, United States
Florida Cancer Specialists / Sarah Cannon Research Institute, Sarasota, Florida, United States
Department of Investigator Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Cancer Therapy and Research Center (CTRC), The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, , Germany
Contact Details
Name: Study Director
Affiliation: Takeda
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
